Exicure FCF Growth

What does Exicure do? Exicure, Inc. generates revenue through the development and commercialization of therapeutic products based on its Spherical Nucleic Acid (SNA) technology. The company focuses on immuno-oncology, genetic disorders, and other indications, with a pipeline including AST-008, XCUR-FXN, and XCUR17. AST-008 is a toll-like receptor 9 agonist designed to activate the innate immune system and induce anti-cancer responses, particularly when combined with checkpoint inhibitors. XCUR-FXN targets Friedreich’s ataxia (FA) in preclinical development, while XCUR17 is an SNA targeting IL-17RA mRNA for inflammatory disorders, Netherton syndrome, and hair loss disorders. The primary buyers of Exicure's products are pharmaceutical companies and healthcare providers seeking innovative treatments for complex conditions. The company's SNA technology enables therapeutic oligonucleotides to work across various cells and tissues, addressing unmet medical needs in immuno-oncology and genetic disorders. Commercial partnerships and licensing agreements are likely key revenue streams, though specific partners are not named in the business description. Exicure's product segments include immuno-oncology (AST-008), genetic disorders (XCUR-FXN), and inflammatory conditions (XCUR17). These segments target patients with specific diseases, such as cancer, Friedreich’s ataxia, and inflammatory disorders, where current treatments are limited. The company's focus on SNA technology differentiates its approach, aiming to unlock new therapeutic possibilities in these areas. Exicure is one of the most popular companies on Eulerpool.